We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Trial of Epinephrine and Albuterol in Bronchiolitis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2008 by Kern Medical Center.
Recruitment status was:  Active, not recruiting
ClinicalTrials.gov Identifier:
First Posted: June 16, 2005
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Kern Medical Center

The purpose of this study is to see which of the two most common drugs used to treat bronchiolitis works better. A child's participation in this study is expected to last less than 4 hours. Approximately 600 patients will be recruited to participate in this study at Kern Medical Center (KMC).

Bronchiolitis is a very common lung infection in babies. There are many drugs used to treat this disease but nobody knows which one, if any, works the best. Two of the most commonly used drugs are albuterol and epinephrine. These are both drugs given during breathing treatments with oxygen and a mask. We are doing this study to see which of these drugs works better or if they are both equally good. The study works as follows: after the consent process the baby gets three treatments.

  • Nebulizer 1 (Treatment)
  • Treatment + 30 minutes (approximately) Nebulizer 2
  • Treatment + 60 minutes (approximately) Nebulizer 3
  • Treatment + 120 minutes (approximately)

The baby will be reevaluated and either discharged home or revert to standard therapy. If the baby is discharged directly from the emergency department (E.D.), we will call you in three days time to see how he/she is doing.

Condition Intervention
Bronchiolitis Drug: Epinephrine Drug: albuterol (salbutamol)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Randomized Controlled Trial of Epinephrine and Albuterol in Bronchiolitis

Resource links provided by NLM:

Further study details as provided by Kern Medical Center:

Primary Outcome Measures:
  • Successful hospital discharge at three days

Secondary Outcome Measures:
  • Improvement in severity of disease score
  • Improvement in respiratory status

Estimated Enrollment: 600
Study Start Date: November 2003
Estimated Study Completion Date: May 2006
Detailed Description:
Double blind RCT. Primary outcome measure is admission defined as actual admission or discharge with unscheduled return leading to admission within 72 hours. Secondary endpoints include change in severity of illness and response of respiratory parameters to treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 18 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • A clinical diagnosis of bronchiolitis

Exclusion Criteria:

  • Age greater than 18 months
  • Disease too mild to warrant any treatment
  • Emergent intubation on arrival at the ED
  • Participation within another study within 30 days
  • Refusal of informed parental consent
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00114478

United States, California
Kern Medical Center
Bakersfield, California, United States, 93312
Sponsors and Collaborators
Kern Medical Center
Principal Investigator: Paul Walsh, Paul Walsh, MD MSc(peds) Kern Medical Center, David Geffen School of Medicine, UCLA
Principal Investigator: Paul Walsh Research Director, Emergency Medicine
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00114478     History of Changes
Other Study ID Numbers: KMC03034
First Submitted: June 15, 2005
First Posted: June 16, 2005
Last Update Posted: October 12, 2017
Last Verified: January 2008

Keywords provided by Kern Medical Center:

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections
Epinephryl borate
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Adrenergic beta-Agonists
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents
Vasoconstrictor Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists